Veronika Bachanova, MD
Masonic Cancer Center, University of Minnesota · University of Minnesota · University of Minnesota Medical Center, Fairview
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Veronika Bachanova, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:08 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04855253 · Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLMasonic Cancer Center, University of Minnesota · suspended · DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma · principal investigator
- Ph2NCT03642626 · MT2017-45: CAR-T Cell Therapy for Heme MalignanciesMasonic Cancer Center, University of Minnesota · active not recruiting · Acute Lymphoblastic Leukemia, Large B-cell Lymphoma · principal investigator
- Ph2NCT03125642 · Auto Stem Cell Transplant for Lymphoma PatientsMasonic Cancer Center, University of Minnesota · recruiting · Non-Hodgkin Lymphoma, Hodgkin Lymphoma · principal investigator
- Ph1NCT03019666 · Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHLMasonic Cancer Center, University of Minnesota · completed · Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma · principal investigator
- Ph1/Ph2NCT02370160 · HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or LymphomaMasonic Cancer Center, University of Minnesota · completed · Refractory B-Lineage Leukemia, Relapsed B-Lineage Leukemia, Refractory B-Lineage Lymphoma · principal investigator
- Ph1/Ph2NCT02141451 · ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCLMasonic Cancer Center, University of Minnesota · completed · Diffuse Large B Cell Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT01181258 · Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid MalignanciesMasonic Cancer Center, University of Minnesota · completed · Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia · principal investigator
- Ph1/Ph2NCT00625729 · Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic LeukemiaMasonic Cancer Center, University of Minnesota · terminated · Leukemia, Lymphoma · principal investigator
- Ph2NCT00345865 · Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's LymphomaMasonic Cancer Center, University of Minnesota · completed · Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- MT2007-12: ALLOGENEIC NATURAL KILLER CELLS WITH RITUXIMAB IN PATIENTS WITH CD20M01RR000400 · NCRR · UNIVERSITY OF MINNESOTA · fiscal years 2008 · $3,114 awarded in 2008Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Off-the-shelf iPSC-Derived Natural Killer Cell Immunotherapies for AMLP01CA065493 · NCI · UNIVERSITY OF MINNESOTA · PI Jeffrey S. Miller · fiscal years 1995 to 2026Named on NCT00625729
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.